Including Langerhans cell histiocytosis in the differential diagnosis of skin tumors with osteoclast-like multinucleated giant cells

2017 ◽  
Vol 44 (7) ◽  
pp. 659-661
Author(s):  
Tina Ho ◽  
Jennifer Oliver-Krasinski ◽  
Pierre Russo ◽  
Jesse Taylor ◽  
Jenna Streicher ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Langerhans Cell Histiocytosis ◽  
Giant Cells ◽  
Langerhans Cell ◽  
Skin Tumors ◽  
Multinucleated Giant Cells

Multinucleated giant cells in Langerhans cell histiocytosis

2016 ◽  
Vol 174 (1) ◽  
pp. 7-7 ◽  
Author(s):  
Ryu Yanagisawa ◽  
Yoshifumi Ogiso ◽  
Yosuke Miyairi ◽  
Kazuo Sakashita ◽  
Hiroaki Shigeta
Keyword(s):  
Langerhans Cell Histiocytosis ◽  
Giant Cells ◽  
Langerhans Cell ◽  
Multinucleated Giant Cells

Primary cerebral non-Langerhans cell histiocytosis: MRI and differential diagnosis

2002 ◽  
Vol 44 (9) ◽  
pp. 759-763 ◽  
Author(s):  
U. Ernemann ◽  
M. Skalej ◽  
M. Hermisson ◽  
M. Platten ◽  
R. Jaffe ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Langerhans Cell Histiocytosis ◽  
Langerhans Cell

Langerhans cell histiocytosis in childhood – Review, symptoms in the oral cavity, differential diagnosis and report of two cases

2014 ◽  
Vol 42 (2) ◽  
pp. 93-100 ◽  
Author(s):  
Vlasta Merglová ◽  
Daniel Hrušák ◽  
Ludmila Boudová ◽  
Petr Mukenšnabl ◽  
Eva Valentová ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Oral Cavity ◽  
Langerhans Cell Histiocytosis ◽  
Langerhans Cell

scholarly journals Lung cysts in chronic paracoccidioidomycosis

2013 ◽  
Vol 39 (3) ◽  
pp. 368-372 ◽  
Author(s):  
Andre Nathan Costa ◽  
Edson Marchiori ◽  
Gil Benard ◽  
Mariana Sponholz Araujo ◽  
Bruno Guedes Baldi ◽  
...  
Keyword(s):  
Differential Diagnosis ◽  
Retrospective Analysis ◽  
Interstitial Pneumonia ◽  
Langerhans Cell Histiocytosis ◽  
Lung Diseases ◽  
Lung Parenchyma ◽  
Langerhans Cell ◽  
Lung Cysts ◽  
Cystic Lung ◽  
Lymphocytic Interstitial Pneumonia

On HRCT scans, lung cysts are characterized by rounded areas of low attenuation in the lung parenchyma and a well-defined interface with the normal adjacent lung. The most common cystic lung diseases are lymphangioleiomyomatosis, Langerhans cell histiocytosis, and lymphocytic interstitial pneumonia. In a retrospective analysis of the HRCT findings in 50 patients diagnosed with chronic paracoccidioidomycosis, we found lung cysts in 5 cases (10%), indicating that patients with paracoccidioidomycosis can present with lung cysts on HRCT scans. Therefore, paracoccidioidomycosis should be included in the differential diagnosis of cystic lung diseases.

scholarly journals Pediatric Langerhans Cell Histiocytosis (LCH) Clinical Outcome in Hospital Civil De Guadalajara, México

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4951-4951 ◽  
Author(s):  
Katterine Rojas Rodríguez ◽  
Veronica Soto ◽  
Carlos Rodriguez-Galindo ◽  
Paola M. Friedrich ◽  
Edwin Guzmán ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Langerhans Cell Histiocytosis ◽  
Disease Risk ◽  
Conflicts Of Interest ◽  
Systemic Disease ◽  
Giant Cells ◽  
Langerhans Cell ◽  
Induction Treatment ◽  
Multisystem Disease ◽  
Clonal Proliferation

Abstract Pediatric Langerhans cell histiocytosis (LCH) clinical outcome in Hospital Civil de Guadalajara, México. Introduction : LCH results from clonal proliferation of functionally and immunophenotyped inmature round Langerhans cells along with eosinophiles, machrophages, lymphocytes and ocasionally multinucleated giant cells (1). Its incidence is 2-10 cases by million of children below 15 yr in US (2). Our objective was to describe the clinical characteristics and treatment outcome of patients with LCH at Departement of Hematology-Oncology of Hospital Civil de Guadalajara México. Methods: It was a retrospective design and 41 pediatric patients below 18 yr were included. The diagnosis was corroborated by pathology and immunohistochemistry. Variables as age, gender, localised vs systemic disease, risk organ commitment, global survival (GS) and event free survival (EFS) were analysed. We used descriptive and inferencial statistics with SPSS program. Results: There were included 41 patients from January 1st 2012 to December 31st 2017. Relation male:female was 1.1:1. Mean presentation was localised disease (58%). Bone was the principal affected structure (34%) and it was 71% to be combined with lung, lymph node and CNS compromise. Risk organ commitment was presented in 32%, being more frecquent bone marrow and liver in 22% each one. Time induction treatment was equal or below 12 weeks in 66% of patients. The 25% of patients had reactivation of LCH, with similar lesions to the beggining in 19.5%. We found statistically significant differences between dead patients (DP) (14.6%) and not dead patients (NDP) (85.4%) in clinical presentation: localised (0% in DP vs 69% in NDP) and systemic disease (100% vs 31%) (p=0,003) and risk organ commitment (100% in DP vs 20% in NDP) (p=0,000). Median age of 13 vs 24 months was for DP and NDP respectively. Conclusion: Dead patients were younger than 13 months old, with systemic disease, and risk organ commitment. We found a later asking of medical advice in DP (6 months) vs NDP (2 months). Keys words: langerhans cell histiocytosis, multisystem disease, risk organ Figure. Figure. Disclosures No relevant conflicts of interest to declare.

scholarly journals Langerhans cell histiocytosis as differential diagnosis of a mediastinal tumor

2008 ◽  
Vol 33 (3) ◽  
pp. 516-517 ◽  
Author(s):  
René Fahrner ◽  
Beatrix Hoksch ◽  
Mathias Gugger ◽  
Ralph Alexander Schmid
Keyword(s):  
Differential Diagnosis ◽  
Langerhans Cell Histiocytosis ◽  
Mediastinal Tumor ◽  
Langerhans Cell

Erdheim—Chester Disease

2003 ◽  
Vol 7 (2) ◽  
pp. 129-132
Author(s):  
Susan E. Lenahan ◽  
Klaus F. Helm ◽  
Kenneth D. Hopper
Keyword(s):  
Differential Diagnosis ◽  
Case Report ◽  
Langerhans Cell Histiocytosis ◽  
Langerhans Cell ◽  
Morbidity And Mortality ◽  
Significant Morbidity ◽  
Erdheim Chester Disease ◽  
Pathologic Findings ◽  
Erdheim Chester ◽  
Chester Disease

Background: Erdheim–Chester disease is a rare non-Langerhans' cell histiocytosis. Objective: This case report is presented to familiarize clinicians with Erdheim–Chester disease and its differential diagnosis. Results and Conclusion: Erdheim–Chester disease presents with unique clinical and pathologic findings. Its xanthoma-like lesions can cause significant morbidity and mortality.

Nonepithelial skin tumors with multinucleated giant cells

2013 ◽  
Vol 30 (1) ◽  
pp. 58-72 ◽  
Author(s):  
María del Carmen Gómez-Mateo ◽  
Carlos Monteagudo
Keyword(s):  
Giant Cells ◽  
Skin Tumors ◽  
Multinucleated Giant Cells

scholarly journals Presence of osteoclast-like multinucleated giant cells in the bone and nonostotic lesions of Langerhans cell histiocytosis

2005 ◽  
Vol 201 (5) ◽  
pp. 687-693 ◽  
Author(s):  
Cristiana E.T. da Costa ◽  
Nicola E. Annels ◽  
Claudia M.J.M. Faaij ◽  
Ramses G. Forsyth ◽  
Pancras C.W. Hogendoorn ◽  
...  
Keyword(s):  
Langerhans Cell Histiocytosis ◽  
Myeloid Cell ◽  
Cathepsin K ◽  
Nuclear Factor Κb ◽  
Giant Cells ◽  
Langerhans Cell ◽  
Bone Lesions ◽  
Tartrate Resistant Acid Phosphatase ◽  
Tissue Destruction ◽  
Organ Systems

Langerhans cell histiocytosis (LCH) is a disease that can involve one or multiple organ systems characterized by an accumulation of CD1a+ Langerhans-like cells as well as several other myeloid cell types. The precise origin and role of one of these populations, the multinucleated giant cell (MGC), in this disease remains unknown. This work shows that in three different lesional tissues, bone, skin, and lymph node, the MGCs expressed the characteristic osteoclast markers, tartrate-resistant acid phosphatase and vitronectin receptor, as well as the enzymes cathepsin K and matrix metalloproteinase-9. Although, in bone lesions, the osteoclast-like MGCs were only CD68+, in the nonostotic sites, they coexpressed CD1a. The presence of osteoclast-like MGCs may be explained by the production of osteoclast-inducing cytokines such as receptor activator of nuclear factor κB ligand and macrophage colony-stimulating factor by both the CD1a+ LCH cells and T cells in these lesions. As osteoclast-derived enzymes play a major role in tissue destruction, the osteoclast-like nature of MGCs in all LCH lesions makes them a potential target for the treatment of this disease.

Sign in / Sign up

Export Citation Format

Share Document